|CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment|
Y Jin, Z Desta, V Stearns, B Ward, H Ho, KH Lee, T Skaar, AM Storniolo, ...
Journal of the National Cancer Institute 97 (1), 30-39, 2005
|Clinical significance of the cytochrome P450 2C19 genetic polymorphism|
Z Desta, X Zhao, JG Shin, DA Flockhart
Clinical pharmacokinetics 41, 913-958, 2002
|Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine|
V Stearns, MD Johnson, JM Rae, A Morocho, A Novielli, P Bhargava, ...
Journal of the National Cancer Institute 95 (23), 1758-1764, 2003
|Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes|
MP Goetz, JM Rae, VJ Suman, SL Safgren, MM Ames, DW Visscher, ...
Journal of Clinical Oncology 23 (36), 9312-9318, 2005
|Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6|
Z Desta, BA Ward, NV Soukhova, DA Flockhart
Journal of Pharmacology and Experimental Therapeutics 310 (3), 1062-1075, 2004
|Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with …|
BP Schneider, M Wang, M Radovich, GW Sledge, S Badve, A Thor, ...
Journal of Clinical Oncology 26 (28), 4672, 2008
|The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate …|
BA Ward, JC Gorski, DR Jones, SD Hall, DA Flockhart, Z Desta
Journal of Pharmacology and Experimental Therapeutics 306 (1), 287-300, 2003
|The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen|
MP Goetz, SK Knox, VJ Suman, JM Rae, SL Safgren, MM Ames, ...
Breast cancer research and treatment 101, 113-121, 2007
|Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment|
S Borges, Z Desta, L Li, TC Skaar, BA Ward, A Nguyen, Y Jin, ...
Clinical Pharmacology & Therapeutics 80 (1), 61-74, 2006
|Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen|
MD Johnson, H Zuo, KH Lee, JP Trebley, JM Rae, RV Weatherman, ...
Breast cancer research and treatment 85, 151-159, 2004
|Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3': 5'-monophosphate-dependent protein kinase|
JD Corbin, PH Sugden, L West, DA Flockhart, TM Lincoln, D McCarthy
Journal of Biological Chemistry (USA), 1978
|Drug interactions: cytochrome P450 drug interaction table|
Indiana University School of Medicine 2010, 2007
|Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges|
RA Wilke, DW Lin, DM Roden, PB Watkins, D Flockhart, I Zineh, ...
Nature reviews Drug discovery 6 (11), 904-916, 2007
|Regulatory mechanisms in the control of protein kinase|
DA Flockhart, JD Corbin
Critical reviews in biochemistry 12 (2), 133-186, 1982
|Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays|
JM Rae, MD Johnson, ME Lippman, DA Flockhart
Journal of Pharmacology and Experimental Therapeutics 299 (3), 849-857, 2001
|Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen|
YC Lim, Z Desta, DA Flockhart, TC Skaar
Cancer chemotherapy and pharmacology 55, 471-478, 2005
|Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer|
NL Henry, F Azzouz, Z Desta, L Li, AT Nguyen, S Lemler, J Hayden, ...
Journal of Clinical Oncology 30 (9), 936, 2012
|Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants|
JE Tanus-Santos, M Desai, DA Flockhart
Pharmacogenetics and Genomics 11 (8), 719-725, 2001
|Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications|
S Bernard, KA Neville, AT Nguyen, DA Flockhart
The oncologist 11 (2), 126-135, 2006
|Pharmacogenomics: challenges and opportunities|
DM Roden, RB Altman, NL Benowitz, DA Flockhart, KM Giacomini, ...
Annals of internal medicine 145 (10), 749-757, 2006